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Abstract
Influenza vaccination is a cornerstone of influenza prevention efforts among pregnant women. 
Prior to 2005, data from studies conducted on pregnant women were limited, with much of the 
supporting evidence coming from influenza vaccine studies conducted among nonpregnant, age-
matched populations. Since 2005, however, an increasing number of studies have demonstrated 
the safety and immunogenicity of influenza vaccine for pregnant women, including evidence of 
maternal transfer of antibody. In addition, the clinical benefit of influenza vaccination, both for the 
mother and infant, was demonstrated in a landmark randomized clinical trial conducted in 
Bangladesh. Additional randomized clinical trials with laboratory-confirmed influenza as the 
primary outcome are underway in countries without a current influenza vaccination program, but 
such trials are unlikely to be conducted in the United States or other countries that already 
recommend the vaccination of pregnant women. However, current evidence supports the safety 
and immunogenicity of inactivated influenza vaccine and its effectiveness in reducing the risk of 
influenza-related illness among pregnant women.
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Pregnancy places women at increased risk for severe complications from influenza virus 
infection.1,2 Beginning as early as 1960, influenza vaccination has been recommended for 
pregnant women to prevent influenza virus infection and its complications.3 Since 2004, the 
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization 
Practices, the American College of Obstetricians and Gynecologists, and other professional 
organizations have recommended that all pregnant women receive the trivalent inactivated 
vaccine, regardless of pregnancy trimester4 to avoid missed opportunities for vaccination.
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We critically evaluated published literature on the safety, immunogenicity, and clinical 
benefits to the mother of influenza vaccination during pregnancy. Because only the 
inactivated vaccine is recommended in pregnancy, this review includes only results from 
studies evaluating the inactivated influenza vaccine.
We reviewed studies assessing the immunogenicity of influenza vaccine in pregnant women 
and studies of clinical impact of vaccination on pregnant women. Immunogenicity studies 
measure the level of influenza-specific antibody elicited after vaccination, with 
hemagglutination inhibition (HI) testing of pre- and postvaccination serum samples being 
the most commonly used test for assessing influenza vaccine immune response. Although 
there is no specific HI titer level above which infection will not occur, higher 
postvaccination antibody titers correspond with lower risk of influenza illness. And HI titers 
of 1:40 or greater, or a 4-fold rise in HI titer are often used in clinical trials as benchmarks 
for defining an acceptable immune response.
Clinical studies, including observational and randomized trials, measure the ability of the 
vaccine to prevent illness. The primary clinical outcome in vaccine trials may be nonspecific 
(eg, acute respiratory illness) or specific (eg, laboratory-confirmed influenza illness). 
Randomized, double-blind, placebo-controlled study designs provide the strongest evidence 
for benefit. Although observational studies can provide important data, interpretation can be 
complicated because of the differences among persons who choose or choose not to receive 
influenza vaccination.
Efficacy refers to the ability of the vaccine to prevent illness in the context of randomized 
clinical trials, whereas effectiveness refers to the ability of vaccine to prevent illness in 
vaccinated populations outside a randomized clinical trial. Various factors affect the 
observed effectiveness and efficacy of the influenza vaccine. Characteristics of the recipient, 
such as age, immune status, and, potentially, pregnancy status, may influence efficacy and 
effectiveness. Characteristics of the virus, including the match between the vaccine and the 
circulating influenza virus and vaccine immunogenicity, which can vary greatly from year to 
year, can affect vaccine efficacy and effectiveness. In addition, the specific clinical outcome 
being measured may affect the estimate of efficacy or effectiveness. For example, because 
acute respiratory illness may be caused by a number of different pathogens that the vaccine 
would not be expected to prevent, the point estimate of effectiveness is expected to be lower 
because outcomes other than laboratory-confirmed influenza are used.4
Efficacy of inactivated influenza vaccine among adults has been demonstrated in several 
randomized placebo-controlled trials with the outcome of laboratory-confirmed 
influenza.5–12 A recent meta-analysis reported a pooled vaccine efficacy of 59% (95% 
confidence interval, 51–67%) for the trivalent inactivated influenza vaccine among adults 
aged 18–64 years.13 Among studies that enrolled participants with similar age distributions 
to those of pregnant women, demonstrated vaccine efficacy ranged from 54% to 89%.9–12 A 
2-year study among healthy workers younger than 65 years found no efficacy in year 1 when 
the vaccine match was poor but found 86% efficacy against influenza-like illnesses (ILI) 
plus serologically confirmed influenza in year 2.Also,in year 2, vaccinated adults had 34% 
fewer ILIs, 42% fewer physician visits for ILI, and 32% fewer lost workdays for ILI.6 Most 
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recently, a group of investigators in Michigan conducted double-blind, randomized studies 
comparing placebo, live attenuated vaccine, and inactivated vaccine among healthy adults 
younger than 50 years of age. Over 3 influenza seasons, inactivated influenza vaccine 
efficacy ranged from 54% to 77%.9–11
Although the efficacy and effectiveness of influenza vaccination in preventing influenza 
infection and illness has been demonstrated in nonpregnant, healthy adults, the immune 
response to vaccination might be different in pregnant women for several reasons. During 
pregnancy, immune alterations that allow the mother to tolerate fetal tissue of paternal origin 
occur. Although these immune alterations are not well understood, a shift away from cell-
mediated immunity and toward humoral immunity is thought to occur.14 Although these 
immune changes are not expected to affect the efficacy or effectiveness of vaccines in 
pregnancy, it is important to carefully review influenza vaccination studies conducted 
among pregnant women.
Several immunogenicity studies have been conducted in pregnant women dating back to the 
early 1960s. In 1962–1963, Hulka15 conducted a nonrandomized cohort study in which 225 
pregnant and 44 nonpregnant women received either 2 doses of whole virus-inactivated 
influenza vaccine or a placebo. The pattern of rise and fall of influenza titer levels was 
similar in pregnant and nonpregnant women. In 1976–1977, Murray et al16 conducted a 
prospective cohort study using monovalent, whole-virus–inactivated vaccine. Using HI 
antibody testing, the postimmunization geometric mean antibody titers were not 
significantly different in 26 pregnant and 18 nonpregnant women, with no significant 
differences in antibody titers by trimesters. Also in 1976–1977, Sumaya and Gibbs17 
identified 40 pregnant women who had been vaccinated with monovalent whole-virus–
inactivated vaccine and had available serum samples. Results of HI antibody testing showed 
antibody response among the pregnant women to be similar to that of nonpregnant adults 
who participated in a national vaccine trial.
In 1992–1993, Englund et al18 conducted a prospective cohort study in which 13 pregnant 
women in the third trimester were vaccinated with trivalent inactivated influenza vaccine. 
Maternal seroconversion to vaccine antigen was found in all 13 vaccinated pregnant women. 
As part of a randomized controlled clinical trial in Bangladesh, Steinhoff et al19 tested 
samples from 311 pregnant women using an HI assay. Vaccinated pregnant women had 
higher levels of protective influenza antibodies compared with pregnant women who 
received the control vaccine. Jackson et al20 randomly assigned 120 pregnant women to 
receive either a low or high dose of 2009 H1N1 monovalent inactivated vaccine in a 2 dose 
series. One dose of either vaccine elicited an antibody response typically associated with 
protection against influenza infection. Similarly, Tsatsaris et al21 (n = 102) and Fisher et al22 
(n = 14) found protective levels of antibody in healthy pregnant women who received the 
2009 H1N1 monovalent vaccine.
In summary, these studies consistently show that pregnant women administered influenza 
vaccine develop protective concentrations of antiinfluenza antibodies, similar to 
nonpregnant women.
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In addition to the immunogenicity studies, several clinical trials have evaluated the ability of 
influenza vaccine to prevent illness in pregnant women. However, until 2008 when the 
Mother’s Gift Project,23 a randomized trial, was published, much of the information about 
the clinical benefits of vaccinating pregnant women came from observational studies that 
used nonspecific, non-laboratory-confirmed outcomes and failed to demonstrate a benefit of 
vaccination.
The cohort study by Hulka15 in 1962–1963 included both prospective and retrospective 
components. For the prospective portion of the study, he vaccinated pregnant and 
nonpregnant women with whole-virus–inactivated vaccine and also vaccinated pregnant and 
nonpregnant women with placebo. His study also included a retrospective component in 
which all women attending the prenatal clinic in April 1963 who were not part of the 
prospective component were asked whether they had been vaccinated against influenza the 
preceding winter. Participating nonvaccinated women were added to the prospective control 
group and were asked whether they had experienced influenza-like illness defined as flu 
with fever. Eleven percent of the vaccinated pregnant women compared with 20% of the 
nonvaccinated pregnant women reported influenza-like illness; this difference was not 
statistically significant.
Black et al24 conducted a retrospective analysis of outpatient visits and hospitalizations at 
Kaiser Permanente spanning 5 influenza seasons using an administrative database (1997–
2002). They found a low burden of medical care for influenza-like illness (defined based on 
International Classification of Diseases (ninth revision)-coded medical visits) with no 
pregnant women hospitalized with a diagnosis of influenza during the study period and only 
9 of 49,585 pregnant women hospitalized with a diagnosis of pneumonia during influenza 
season. Furthermore, women who received influenza vaccination had the same risk for 
outpatient visits for influenza-like illness compared with unvaccinated pregnant women 
(hazard ratio, 1.15; P = .088).
The main limitation of this study is that this type of administrative data does not accurately 
distinguish influenza from other respiratory illness, thereby including nonspecific endpoints, 
and therefore, any effect of influenza vaccine would likely be substantially underestimated. 
Munoz et al25 conducted a retrospective review of 5 influenza seasons (1998–2003) at a 
large, multidisciplinary clinic in Houston, TX, and compared 225 vaccinated pregnant 
women with 826 nonvaccinated pregnant women, matched by age, month of delivery, and 
type of medical insurance. There were no significant differences in medical visits for acute 
respiratory infections between vaccinated and unvaccinated women, with 23% (51 of 225) 
of vaccinated women compared with 19% (156 of 826) of unvaccinated women seeking 
medical care for an acute respiratory infection (P = .24). This is another example of a study 
that used a very nonspecific outcome.
The landmark randomized clinical study among pregnant women was conducted in 2004–
2005 in Bangladesh. In the Mother’s Gift Project,23 pregnant women were randomized to 
receive either inactivated influenza vaccine (n = 172) or pneumococcal vaccine (n = 168). 
Pregnant women who received influenza vaccine were 36% (95% confidence interval 4–
57%) less likely to have respiratory illness with fever compared with those who received 
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pneumococcal vaccine; the study did not include an influenza laboratory–confirmed 
outcome for the mothers. Because of its randomized design and use of a control vaccine, this 
study provides the strongest evidence of maternal benefit of influenza vaccine. Although 
laboratory-confirmed influenza was not included as an outcome in the mothers, it was 
included as an outcome in the infants. Infants younger than 6 months of age were found to 
have a 63% lower risk of laboratory-confirmed influenza. The less specific outcome used for 
the mothers would have underestimated the point estimate of efficacy for influenza vaccine.
The Mother’s Gift Project, because of its large size and randomized design, provides the 
most direct and compelling evidence of the maternal benefits of influenza vaccination in 
pregnancy. Additional information regarding the maternal benefits of influenza vaccination 
in different settings is needed, and several randomized trials on the efficacy of influenza in 
pregnant women are currently underway (Clinicaltrials.gov, #NCT01430689 and 
#NCT01034254).
In summary, because pregnant women are at increased risk for influenza-associated 
complications,26 it is important to reduce the risk of influenza infection among pregnant 
women. Influenza vaccination is an important component of prevention efforts among 
pregnant women. Although few data on clinical efficacy are available from randomized 
trials in pregnant women, immunogenicity studies in pregnant women, results from clinical 
effectiveness studies in similarly aged nonpregnant adults, and studies demonstrating the 
clinical benefits to infants all support efforts to vaccinate pregnant women.
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